Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026

Skye Bioscience (Nasdaq: SKYE) will report 2025 fourth-quarter and full-year financial results and provide a business update on March 10, 2026.

Rhea-AI Summary

Skye Bioscience (Nasdaq: SKYE) will report 2025 fourth-quarter and full-year financial results and provide a business update on March 10, 2026. A press release will be issued after market close, followed by a conference call at 1:30 p.m. PT / 4:30 p.m. ET.

Investors can access a live webcast, financial tables, and an investor presentation on Skye's Investor Relations website; a replay and transcript will be posted after the call.

Argus Mar 5 session

-0.35% close to close Open Argus

Details

News Market Reaction – SKYE

In the Mar 5 session, SKYE declined 0.35%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets March 10, 2026 as the date for Skye’s 2025 fourth-quarter and full-year resul...

Analysis

This announcement sets March 10, 2026 as the date for Skye’s 2025 fourth-quarter and full-year results call, scheduled for 1:30 p.m. PT/4:30 p.m. ET. It follows a series of clinical, strategic, and collaboration updates around nimacimab and obesity programs. Investors may focus on detailed financials, cash usage, and how management frames upcoming Phase 2b plans and milestones compared with prior CBeyond and corporate outlook disclosures.

Key Figures

Earnings call date: March 10, 2026 Earnings call time PT: 1:30 p.m. PT Earnings call time ET: 4:30 p.m. ET +1 more

Earnings call date

March 10, 2026

2025 Q4 and full-year results announcement

Earnings call time PT

1:30 p.m. PT

Start time of conference call

Earnings call time ET

4:30 p.m. ET

Start time of conference call

Call arrival window

5–10 minutes

Recommended early join time before call

Historical Context

5 past events · Latest: Feb 02

5 events

1. Feb 02

   Phase 2a extension

   24h Move

   -7.9%

   Interim 52-week CBeyond extension data showing 22.3% mean weight loss combo.

2. Jan 29

   Preclinical data

   24h Move

   -5.0%

   Preclinical nimacimab data at Keystone Obesity conference in DIO mouse models.

3. Jan 21

   Conference poster

   24h Move

   +0.8%

   Announcement of upcoming poster on nimacimab in obesity models at Keystone.

4. Jan 12

   Corporate outlook

   24h Move

   -4.0%

   2026 outlook detailing CBeyond extension updates and planned Phase 2b study.

5. Jan 05

   Collaboration deal

   24h Move

   -2.3%

   Global collaboration with Halozyme to use ENHANZE for nimacimab delivery.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Tuesday, March 10th at 1:30 p.m. PT/4:30 p.m. ET to discuss its 2025 fourth quarter and full-year financial results and business update. An earnings press release will be issued after the market closes on March 10th.

The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Please join the call 5-10 minutes prior to the scheduled start time. Following the call, a replay and transcript will be available at the same website.

About Skye Bioscience

Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.

CONTACTS

Investor Relations

ir@skyebioscience.com
(858) 410-0266

LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306

Media Inquiries

LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(415) 269-7757

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Skye Bioscience (SKYE) announce its Q4 and full-year 2025 results?

Skye will release 2025 fourth-quarter and full-year results on March 10, 2026, after market close. According to the company, a conference call will follow on the same day at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and business update.

How can investors access the Skye Bioscience (SKYE) earnings call on March 10, 2026?

Investors can join the live webcast via Skye's Investor Relations website and call in for the conference. According to the company, the webcast will include the earnings press release, financial tables, and an investor presentation.

Will Skye Bioscience (SKYE) provide financial tables and investor presentation with the March 10, 2026 release?

Yes. The company will post financial tables and an investor presentation alongside the earnings press release. According to the company, these materials will be available on the Skye Investor Relations website at the time of the release.

What time should I join the Skye Bioscience (SKYE) March 10, 2026 conference call?

Join the call 5–10 minutes early; it starts at 1:30 p.m. PT / 4:30 p.m. ET. According to the company, arriving early ensures uninterrupted access to the live webcast and any dial-in procedures.

Will a replay or transcript be available after Skye Bioscience's (SKYE) March 10, 2026 call?

Yes. A replay and transcript will be posted after the conference call on the Skye Investor Relations website. According to the company, both the replay and transcript will remain accessible following the live event.

What topics will Skye Bioscience (SKYE) cover in the March 10, 2026 webcast?

The webcast will cover 2025 fourth-quarter and full-year financial results and a business update. According to the company, the call will discuss financial results and related investor materials including financial tables and an investor presentation.